ABSTRACT
Quetiapine is one of the drugs used most in current Psychiatry due to its therapeutic efficiency and clinical safety. We report the case of a 26-year-old male patient with severe mental retardation due to Y-chromosome partial deletion who initiated treatment with quetiapine for the control of his aggressiveness, and who developed severe rhabdomyolysis two weeks later. In spite of the confirmed clinical safety of quetiapine, doctors must monitor the appearance of rare but serious adverse effects as that presented in this clinical case.
Subject(s)
Antipsychotic Agents/adverse effects , Dibenzothiazepines/adverse effects , Rhabdomyolysis/chemically induced , Adult , Humans , Male , Quetiapine FumarateABSTRACT
La quetiapina es uno de los fármacos más empleados en la Psiquiatría actual, debido a su eficacia terapéutica y seguridad clínica. Presentamos el caso de un paciente de 26años, con retraso mental grave debido a deleción parcial del cromosoma Y, que inicia tratamiento con quetiapina parael control de su agresividad, y que desarrolla a las 2 semanas una rabdomiólisis severa. A pesar de la seguridad clínica contrastada de la quetiapina, los médicos deben vigilar laaparición de raros pero graves efectos adversos como el presentado en este caso clínico (AU)
Quetiapine is one of the most used drugs in current Psychiatry, due to its therapeutic efficiency and clinical safety. We report the case of a 26-year-old patient, serious mental retardation due to Y-chromosome partial deletion, that initiates treatment with quetiapine for the control of his aggressiveness, and that develops severe rhabdomyolysis two weeks later. In spite of the clinical safety confirmed of quetiapine, doctors must monitor the appearance of rare but serious adverse effects as the presented one in this clinical case (AU)
